Published in Metabolism on February 12, 2010
Hyperglycemia induces Toll-like receptor-2 and -4 expression and activity in human microvascular retinal endothelial cells: implications for diabetic retinopathy. J Diabetes Res (2014) 1.61
Knockout of toll-like receptor-2 attenuates both the proinflammatory state of diabetes and incipient diabetic nephropathy. Arterioscler Thromb Vasc Biol (2011) 1.34
The role of TLR2 and 4-mediated inflammatory pathways in endothelial cells exposed to high glucose. PLoS One (2014) 0.97
The Role of Toll-Like Receptors in Diabetes-Induced Inflammation: Implications for Vascular Complications. Curr Diab Rep (2012) 0.96
The Emerging Role of TLR and Innate Immunity in Cardiovascular Disease. Cardiol Res Pract (2012) 0.95
Hyperglycemia induces Toll like receptor 4 expression and activity in mouse mesangial cells: relevance to diabetic nephropathy. Am J Physiol Renal Physiol (2012) 0.95
Expression of Toll-Like Receptor 4 in Glomerular Endothelial Cells under Diabetic Conditions. Acta Histochem Cytochem (2013) 0.88
Burkholderia pseudomallei triggers altered inflammatory profiles in a whole-blood model of type 2 diabetes-melioidosis comorbidity. Infect Immun (2012) 0.86
Toll-like receptor expression and signaling in human diabetic wounds. World J Diabetes (2014) 0.82
Requirement for TLR2 in the development of albuminuria, inflammation and fibrosis in experimental diabetic nephropathy. Int J Clin Exp Pathol (2014) 0.81
Resveratrol ameliorates experimental periodontitis in diabetic mice through negative regulation of TLR4 signaling. Acta Pharmacol Sin (2014) 0.78
Macrophage-dependent IL-1β production induces cardiac arrhythmias in diabetic mice. Nat Commun (2016) 0.78
High glucose induces and activates Toll-like receptor 4 in endothelial cells of diabetic retinopathy. Diabetol Metab Syndr (2015) 0.77
Toll-like receptor 2 mediates vascular contraction and activates RhoA signaling in vascular smooth muscle cells from STZ-induced type 1 diabetic rats. Pflugers Arch (2015) 0.77
TAK-242, a Toll-Like Receptor 4 Antagonist, Protects against Aldosterone-Induced Cardiac and Renal Injury. PLoS One (2015) 0.76
Expression of toll-like receptor 2 in glomerular endothelial cells and promotion of diabetic nephropathy by Porphyromonas gingivalis lipopolysaccharide. PLoS One (2014) 0.75
Toll-like receptor 2 agonist exacerbates renal injury in diabetic mice. Exp Ther Med (2017) 0.75
An ancestral retroviral protein identified as a therapeutic target in type-1 diabetes. JCI Insight (2017) 0.75
Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci U S A (2004) 5.58
Modulation of atherosclerosis in mice by Toll-like receptor 2. J Clin Invest (2005) 3.91
Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. J Clin Endocrinol Metab (2007) 2.84
Increase in plasma endotoxin concentrations and the expression of Toll-like receptors and suppressor of cytokine signaling-3 in mononuclear cells after a high-fat, high-carbohydrate meal: implications for insulin resistance. Diabetes Care (2009) 2.83
Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes (2006) 2.65
Toll-like receptors and innate immunity. J Mol Med (Berl) (2006) 2.65
Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus. Circulation (2005) 2.46
Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes--the EURODIAB Prospective Complications Study. Diabetologia (2005) 2.16
Evidence of increased inflammation and microcirculatory abnormalities in patients with type 1 diabetes and their role in microvascular complications. Diabetes (2007) 1.84
Toll-like receptor 2 plays a critical role in the progression of atherosclerosis that is independent of dietary lipids. Atherosclerosis (2007) 1.67
Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia (1999) 1.67
Acute modulation of toll-like receptors by insulin. Diabetes Care (2008) 1.46
Toll-like receptor 4 in atherosclerosis. J Cell Mol Med (2007) 1.44
Toll-like receptors and atherosclerosis: key contributors in disease and health? Immunol Res (2006) 1.30
Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. J Clin Endocrinol Metab (2007) 2.84
Vitamins E and C are safe across a broad range of intakes. Am J Clin Nutr (2005) 2.72
Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes (2006) 2.65
Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation (2002) 2.50
Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes Care (2010) 2.39
Adiponectin decreases C-reactive protein synthesis and secretion from endothelial cells: evidence for an adipose tissue-vascular loop. Arterioscler Thromb Vasc Biol (2008) 2.29
High glucose induces toll-like receptor expression in human monocytes: mechanism of activation. Diabetes (2008) 2.23
C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation (2003) 2.09
Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation (2006) 2.06
Knockout of toll-like receptor-4 attenuates the pro-inflammatory state of diabetes. Cytokine (2011) 1.91
Retracted Alpha-lipoic acid supplementation and diabetes. Nutr Rev (2008) 1.86
High glucose induces IL-1beta expression in human monocytes: mechanistic insights. Am J Physiol Endocrinol Metab (2007) 1.85
Evidence of increased inflammation and microcirculatory abnormalities in patients with type 1 diabetes and their role in microvascular complications. Diabetes (2007) 1.84
Validation of an immunoassay for soluble Klotho protein: decreased levels in diabetes and increased levels in chronic kidney disease. Am J Clin Pathol (2012) 1.67
Development of an in vitro screening assay to test the antiinflammatory properties of dietary supplements and pharmacologic agents. Clin Chem (2005) 1.53
Oxidative stress and atherosclerosis. Pathophysiology (2006) 1.52
Plasma antioxidant capacity in response to diets high in soy or animal protein with or without isoflavones. Am J Clin Nutr (2005) 1.51
Comparison effect of atorvastatin (10 versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome. Am J Cardiol (2008) 1.51
Hyperglycemia induces monocytic release of interleukin-6 via induction of protein kinase c-{alpha} and -{beta}. Diabetes (2005) 1.50
The evolving role of C-reactive protein in atherothrombosis. Clin Chem (2008) 1.48
Free fatty acids in the presence of high glucose amplify monocyte inflammation via Toll-like receptors. Am J Physiol Endocrinol Metab (2010) 1.45
Contrasting effects of oral versus transdermal estrogen on serum amyloid A (SAA) and high-density lipoprotein-SAA in postmenopausal women. Arterioscler Thromb Vasc Biol (2004) 1.43
Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. J Clin Endocrinol Metab (2006) 1.42
Human C-reactive protein and the metabolic syndrome. Curr Opin Lipidol (2009) 1.40
Quantification of daratumumab in the serum protein electrophoresis. Clin Chem Lab Med (2016) 1.39
CD11c/CD18 expression is upregulated on blood monocytes during hypertriglyceridemia and enhances adhesion to vascular cell adhesion molecule-1. Arterioscler Thromb Vasc Biol (2010) 1.37
Knockout of toll-like receptor-2 attenuates both the proinflammatory state of diabetes and incipient diabetic nephropathy. Arterioscler Thromb Vasc Biol (2011) 1.34
C-reactive protein decreases prostacyclin release from human aortic endothelial cells. Circulation (2003) 1.34
Dietary factors that promote or retard inflammation. Arterioscler Thromb Vasc Biol (2006) 1.32
Gamma-tocopherol supplementation alone and in combination with alpha-tocopherol alters biomarkers of oxidative stress and inflammation in subjects with metabolic syndrome. Free Radic Biol Med (2007) 1.30
The biological effects of CRP are not attributable to endotoxin contamination: evidence from TLR4 knockdown human aortic endothelial cells. J Lipid Res (2006) 1.28
Adipose tissue dysfunction in nascent metabolic syndrome. J Obes (2013) 1.26
Human C-reactive protein induces endothelial dysfunction and uncoupling of eNOS in vivo. Atherosclerosis (2009) 1.26
Adipose tissue dysregulation in patients with metabolic syndrome. J Clin Endocrinol Metab (2011) 1.25
C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling. J Mol Cell Cardiol (2007) 1.25
Alpha-tocopherol decreases superoxide anion release in human monocytes under hyperglycemic conditions via inhibition of protein kinase C-alpha. Diabetes (2002) 1.24
Comparison of the antioxidant effects of Concord grape juice flavonoids alpha-tocopherol on markers of oxidative stress in healthy adults. Am J Clin Nutr (2002) 1.23
Binding and internalization of C-reactive protein by Fcgamma receptors on human aortic endothelial cells mediates biological effects. Arterioscler Thromb Vasc Biol (2005) 1.23
C-reactive protein stimulates superoxide anion release and tissue factor activity in vivo. Atherosclerosis (2008) 1.21
C-reactive protein decreases interleukin-10 secretion in activated human monocyte-derived macrophages via inhibition of cyclic AMP production. Arterioscler Thromb Vasc Biol (2006) 1.21
Elevated plasma high-sensitivity C-reactive protein concentrations in Asian Indians living in the United States. J Clin Endocrinol Metab (2003) 1.19
Metabolic syndrome: an appraisal of the pro-inflammatory and procoagulant status. Endocrinol Metab Clin North Am (2004) 1.17
Innate immunity genes influence the severity of acute appendicitis. Ann Surg (2004) 1.16
C-reactive protein polarizes human macrophages to an M1 phenotype and inhibits transformation to the M2 phenotype. Arterioscler Thromb Vasc Biol (2011) 1.15
A novel dietary triterpene Lupeol induces fas-mediated apoptotic death of androgen-sensitive prostate cancer cells and inhibits tumor growth in a xenograft model. Cancer Res (2005) 1.14
Effect of high-dose alpha-tocopherol supplementation on biomarkers of oxidative stress and inflammation and carotid atherosclerosis in patients with coronary artery disease. Am J Clin Nutr (2007) 1.14
Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role. Curr Opin Nephrol Hypertens (2005) 1.14
Lupeol inhibits growth of highly aggressive human metastatic melanoma cells in vitro and in vivo by inducing apoptosis. Clin Cancer Res (2008) 1.12
CRP and adiponectin and its oligomers in the metabolic syndrome: evaluation of new laboratory-based biomarkers. Am J Clin Pathol (2008) 1.10
Inflammation, atherosclerosis, and psoriasis. Clin Rev Allergy Immunol (2013) 1.10
Macrophage conditioned medium induces the expression of C-reactive protein in human aortic endothelial cells: potential for paracrine/autocrine effects. Am J Pathol (2005) 1.10
Diabetes is a proinflammatory state: a translational perspective. Expert Rev Endocrinol Metab (2010) 1.06
CRP promotes monocyte-endothelial cell adhesion via Fcgamma receptors in human aortic endothelial cells under static and shear flow conditions. Am J Physiol Heart Circ Physiol (2006) 1.04
Defining the proinflammatory phenotype using high sensitive C-reactive protein levels as the biomarker. J Clin Endocrinol Metab (2005) 1.01
Failure of vitamin E in clinical trials: is gamma-tocopherol the answer? Nutr Rev (2005) 1.01
Low vitamin D levels correlate with the proinflammatory state in type 1 diabetic subjects with and without microvascular complications. Am J Clin Pathol (2011) 1.01
C-reactive protein decreases tissue plasminogen activator activity in human aortic endothelial cells: evidence that C-reactive protein is a procoagulant. Arterioscler Thromb Vasc Biol (2005) 1.00
High-fat, energy-dense, fast-food-style breakfast results in an increase in oxidative stress in metabolic syndrome. Metabolism (2008) 1.00
Cocoa products decrease low density lipoprotein oxidative susceptibility but do not affect biomarkers of inflammation in humans. J Nutr (2002) 0.99
Simvastatin (40 mg/day), adiponectin levels, and insulin sensitivity in subjects with the metabolic syndrome. Am J Cardiol (2007) 0.98
Reduced-calorie orange juice beverage with plant sterols lowers C-reactive protein concentrations and improves the lipid profile in human volunteers. Am J Clin Nutr (2006) 0.98
Coenzyme Q10 supplementation and heart failure. Nutr Rev (2007) 0.98
Epigenetic regulation of high glucose-induced proinflammatory cytokine production in monocytes by curcumin. J Nutr Biochem (2010) 0.97
Anti-inflammatory effects of alpha-tocopherol. Ann N Y Acad Sci (2004) 0.97
Effect of C-reactive protein on chemokine expression in human aortic endothelial cells. J Mol Cell Cardiol (2004) 0.97
Statins and biomarkers of inflammation. Curr Atheroscler Rep (2007) 0.96
TLR2 expression and signaling-dependent inflammation impair wound healing in diabetic mice. Lab Invest (2010) 0.96
Supplementation with omega3 polyunsaturated fatty acids and all-rac alpha-tocopherol alone and in combination failed to exert an anti-inflammatory effect in human volunteers. Metabolism (2004) 0.96
Hyperglycemia induces Toll like receptor 4 expression and activity in mouse mesangial cells: relevance to diabetic nephropathy. Am J Physiol Renal Physiol (2012) 0.95
Resveratrol up-regulates SIRT1 and inhibits cellular oxidative stress in the diabetic milieu: mechanistic insights. J Nutr Biochem (2011) 0.95
C-reactive protein stimulates myeloperoxidase release from polymorphonuclear cells and monocytes: implications for acute coronary syndromes. Clin Chem (2008) 0.94
Native pentameric C-reactive protein displays more potent pro-atherogenic activities in human aortic endothelial cells than modified C-reactive protein. Atherosclerosis (2006) 0.94
Candesartan inhibits Toll-like receptor expression and activity both in vitro and in vivo. Atherosclerosis (2008) 0.93
Oxidative stress and antioxidant supplementation in the management of diabetic cardiovascular disease. J Investig Med (2004) 0.93
C-reactive protein induces release of both endothelial microparticles and circulating endothelial cells in vitro and in vivo: further evidence of endothelial dysfunction. Clin Chem (2011) 0.93
Pioglitazone inhibits Toll-like receptor expression and activity in human monocytes and db/db mice. Endocrinology (2009) 0.93
Fisetin Inhibits Osteoclast Differentiation via Downregulation of p38 and c-Fos-NFATc1 Signaling Pathways. Evid Based Complement Alternat Med (2012) 0.93
Therapy and clinical trials: management of diabetic dyslipidemia. Curr Opin Lipidol (2009) 0.92
Alpha-tocopherol decreases tumor necrosis factor-alpha mRNA and protein from activated human monocytes by inhibition of 5-lipoxygenase. Free Radic Biol Med (2005) 0.92
Inhibition of endothelial nitric oxide synthase by C-reactive protein: clinical relevance. Clin Chem (2008) 0.92
C-reactive protein impairs the endothelial glycocalyx resulting in endothelial dysfunction. Cardiovasc Res (2009) 0.92
The effect of weight loss on a stable biomarker of inflammation, C-reactive protein. Nutr Rev (2005) 0.92
Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. J Am Coll Cardiol (2003) 0.91
Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord (2010) 0.91
C-reactive protein and the vascular endothelium: implications for plaque instability. J Am Coll Cardiol (2006) 0.90
Supplementation with a pine bark extract rich in polyphenols increases plasma antioxidant capacity and alters the plasma lipoprotein profile. Lipids (2002) 0.90
Protein tyrosine phosphatase 1B regulates pyruvate kinase M2 tyrosine phosphorylation. J Biol Chem (2013) 0.90
Effects of Aloe vera supplementation in subjects with prediabetes/metabolic syndrome. Metab Syndr Relat Disord (2012) 0.90
Fisetin inhibits hyperglycemia-induced proinflammatory cytokine production by epigenetic mechanisms. Evid Based Complement Alternat Med (2012) 0.89
High-dose alpha-tocopherol therapy does not affect HDL subfractions in patients with coronary artery disease on statin therapy. Clin Chem (2007) 0.88
Hyperhomocysteinemia in Asian Indians living in the United States. J Clin Endocrinol Metab (2003) 0.88
Increased secretion of IP-10 from monocytes under hyperglycemia is via the TLR2 and TLR4 pathway. Cytokine (2009) 0.88
C-reactive protein induces M-CSF release and macrophage proliferation. J Leukoc Biol (2008) 0.88
Plant sterol-fortified orange juice effectively lowers cholesterol levels in mildly hypercholesterolemic healthy individuals. Arterioscler Thromb Vasc Biol (2004) 0.87
Increased adipose tissue insulin resistance in metabolic syndrome: relationship to circulating adipokines. Metab Syndr Relat Disord (2014) 0.87
Role of C-reactive protein in contributing to increased cardiovascular risk in metabolic syndrome. Curr Atheroscler Rep (2010) 0.87
A dose-response study on the effects of purified lycopene supplementation on biomarkers of oxidative stress. J Am Coll Nutr (2008) 0.86